DSS, Inc. has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. The decision follows a careful review of current market conditions and deal terms by management and the Board of Directors. They concluded that proceeding with the offering at this time would not reflect the value DSS believes it is building for shareholders.

The company stated it remains well-positioned to access the capital markets and is committed to doing so on terms that align with its strategic plan. DSS will continue to evaluate financing alternatives and capital markets opportunities as conditions develop. The withdrawal does not indicate any change in the company's business outlook, operating strategy, or confidence in the value of its assets and subsidiaries.

"We are focused on executing our business plan and creating long-term value for our shareholders," said Jason Grady, Chief Executive Officer of DSS, Inc. "Accessing capital on the right terms, at the right time, is an important part of that discipline. We are confident in the direction of the Company and will pursue opportunities that align with where we are headed."

DSS continues to advance several strategic initiatives, including the previously announced merger involving Impact Biomedical. The company believes this merger has the potential to create meaningful long-term value for shareholders. DSS operates across multiple business lines, including product packaging, biotechnology, commercial lending, and securities and investment management.

Strategic Initiatives

• Merger with Impact Biomedical: Aims to create long-term shareholder value.
• Capital Markets Access: Evaluating financing alternatives and opportunities.
• Business Model: Focuses on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings.

The company emphasizes that it will continue to evaluate opportunities to unlock value across its portfolio while maintaining financial and strategic flexibility.